Dietary Management of Non-EoE Eosinophilic Gastrointestinal Diseases.

Elimination diet Eosinophilic enteritis Eosinophilic gastritis Eosinophilic gastrointestinal disease Feeding difficulties Food triggers Malnutrition

Journal

Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635

Informations de publication

Date de publication:
May 2024
Historique:
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 4 4 2024
Statut: ppublish

Résumé

Patients with non-eosinophilic esophagitis eosinophilic gastrointestinal diseases (non-EoE EGIDs) are prone to nutritional deficiencies due to food-avoidant behaviors, malabsorption, and high nutrition impact symptoms. Nutrient deficiencies correspond to the segment, depth, and extent of the gastrointestinal tract involved and can impact organs distant from the gut. Patients with non-EoE EGIDs are often atopic, and some appear to respond to dietary avoidance of specific food allergens. Tests to identify food triggers other than response to elimination diets are lacking. Dietary restriction therapy should be considered in such patients and is best implemented through a multidisciplinary approach to avoid nutritional complications.

Identifiants

pubmed: 38575231
pii: S0889-8561(24)00009-2
doi: 10.1016/j.iac.2024.01.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-396

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure M. Chehade is currently serving or has served as consultant for Regeneron, Adare/Ellodi, AstraZeneca, Sanofi, Bristol Myers Squibb, Recludix Pharma, Nexstone Immunology, Allakos, Shire/Takeda, and Phathom, and is currently receiving or has received research funding from Regeneron, United States, Allakos, Shire/Takeda, AstraZeneca, United Kingdom, Adare/Ellodi, Bristol-Myers Squibb, United States, Danone, v. B. Doerfler has served on speakers bureaus for Nutricia North America, on advisory boards for Trellus Health LLC, and received honoraria from PRIMED CME and ACHL Healthcare. D. Atkins has nothing to disclose.

Auteurs

Mirna Chehade (M)

Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1198, New York, NY 10029, USA. Electronic address: mirna.chehade@mssm.edu.

Bethany Doerfler (B)

Department of Gastroenterology & Hepatology, Northwestern Feinberg School of Medicine, Digestive Health Center, 259 East Erie, Suite 1600, Chicago, IL 60611, USA.

Dan Atkins (D)

Department of Pediatrics, Allergy and Immunology, Gastrointestinal Eosinophilic Diseases Program, University of Colorado School of Medicine, Children's Hospital Colorado, 13123 E. 16th Avenue, Aurora, CO 80045, USA.

Classifications MeSH